Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 2/20 | 0.37 |
| ▸ | AR | P10275 | 2/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20911651 | 0.88 | AAK1 (0.48) | AAK1MAOBMAOAHPGDALDH1A1 | |
| SCHEMBL1331302 | 0.84 | AAK1 (0.55) | AAK1MAOBMAOAXDHAR | |
| SCHEMBL7928285 | 0.83 | HPGD (0.51) | AAK1MAOBMAOAHPGDALDH1A1 | |
| SCHEMBL4456952 | 0.81 | HPGD (0.56) | AAK1MAOBMAOAHPGDALDH1A1 | |
| SCHEMBL430108 | 0.81 | EGFR (0.47) | AAK1MAOBMAOAHPGDALDH1A1 | |
| SCHEMBL27404855 | 0.80 | ALDH1A1 (0.62) | HPGDALDH1A1AR | |
| SCHEMBL14820084 | 0.80 | MAOB (0.45) | AAK1MAOBMAOAHPGDALDH1A1 | |
| SCHEMBL392560 | 0.79 | MAOB (0.47) | AAK1MAOBMAOAHPGDALDH1A1 | |
| SCHEMBL19648612 | 0.79 | MAOB (0.46) | AAK1MAOBMAOAHPGDALDH1A1 | |
| SCHEMBL1909360 | 0.79 | HTR7 (0.47) | AAK1MAOBMAOAHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004459-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2128136-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004459-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | XDH, NUDT1, PNPO | AAK1 1888/4885MAOB 155/4885MAOA 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.